Published in Biotech Law Weekly, August 20th, 2004
Through this agreement, Ablynx will use its unique and patent protected Nanobody platform to discover and develop drug candidates against a G-protein coupled receptor (GPCR) target specified by P&GP.
Nanobodies are a novel class of therapeutics that combines the advantages of conventional antibodies with key features of small-molecule drugs. As the smallest functional fragment of naturally...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.